Latest SEC filings for Gilead Sciences, Inc. (GILD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-16.
Dickinson Andrew D, listed as Chief Financial Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Mercier Johanna, listed as Chief Comm & Corp Aff Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
JOHANNA MERCIER filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
ANDREW DICKINSON filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
O'Day Daniel Patrick, listed as Director, Chairman & CEO at GILEAD SCIENCES, INC., reported an open-market sale of 15,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Mercier Johanna, listed as Chief Comm & Corp Aff Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Dickinson Andrew D, listed as Chief Financial Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
ANDREW DICKINSON filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
JOHANNA MERCIER filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Berger Dietmar (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Cain Wettan Keeley M (EVP Gen Counsel, Legal & Comp) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Dickinson Andrew D (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Mercier Johanna (Chief Comm & Corp Aff Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
O'Day Daniel Patrick (Director, Chairman & CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
O'Day Daniel Patrick, listed as Director, Chairman & CEO at GILEAD SCIENCES, INC., reported an open-market sale of 15,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
DANIEL O'DAY filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.
GILEAD SCIENCES, INC. (10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
GILEAD SCIENCES, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Dickinson Andrew D, listed as Chief Financial Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Mercier Johanna, listed as Chief Comm & Corp Aff Officer at GILEAD SCIENCES, INC., reported an open-market sale of 28,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Executives, directors, and large shareholders must report any purchase or sale of GILD shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.
Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.
The 8-K is an event-driven filing that Gilead Sciences, Inc. must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.
The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Gilead Sciences, Inc.'s financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.
View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the GILD stock analysis page.